# Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

Study · id `cardio:ct-nct02988245` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02988245](<https://clinicaltrials.gov/study/NCT02988245>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02988245

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT02988245. Randomized; single masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2023-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT02988245, source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)
- Planned start: 2022-06 (anticipated) (ClinicalTrials.gov record NCT02988245, source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)
- Primary completion: 2023-05 (anticipated) (ClinicalTrials.gov record NCT02988245, source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)
- Completion: 2023-12 (anticipated) (ClinicalTrials.gov record NCT02988245, source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02988245, source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02988245-2022-02-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension
- Acronym: PGEN for HTN
- Condition: Hypertension
- Intervention (Drug): Geneticure Panel for HTN therapy
- Intervention (Drug): JNC-8
- Lead sponsor: Geneticure, LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Fairview Health Services
- Collaborator class: OTHER
- Collaborator: University of Minnesota
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: University of Minnesota (`cardio:org-university-of-minnesota`)

## Provenance

Content hash: 908c43d63abdc1267c2c7da61fc551a6ed39c8917b4bdb02c49ce9682f7bdeb7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
